Form 4: Director Duncan Receives Stock Options and Restricted Stock Units from Halozyme Therapeutics

Director Barbara Gayle Duncan received 6,501 restricted stock units and an option to purchase 8,804 shares of common stock from Halozyme Therapeutics on April 25, 2024, as part of the company's director compensation program.

Summary

• On April 25, 2024, Barbara Gayle Duncan, a director of Halozyme Therapeutics, Inc., received 6,501 restricted stock units (RSUs) and an option to purchase 8,804 shares of common stock.
• The RSU grant represents the right to receive one share of Halozyme common stock per unit.
• The RSUs will vest fully on the earlier of April 25, 2025, or the date of the company's next annual meeting of stockholders.
• These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan, pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
• The stock option grant has an exercise price of $38.46 per share and will also vest fully on the earlier of April 25, 2025, or the date of the company's next annual meeting of stockholders.
• Following these transactions, Duncan directly owns 15,754 shares of Halozyme common stock and options to purchase 8,804 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The grants of RSUs and stock options align the director's interests with those of the shareholders.
• The vesting schedule encourages continued service as a director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Director compensation packages often include a mix of cash, stock options, and restricted stock units to incentivize performance and align the interests of directors with those of shareholders. This filing reflects a standard practice in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry, but typically include a mix of cash retainers, equity awards (stock options and restricted stock units), and other benefits.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies for their directors.
• The specific value and structure of these packages depend on factors such as company size, performance, and industry benchmarks.

Stakeholder Impact

• The grant of equity to a director aligns their interests with those of shareholders.
• The vesting schedule encourages the director's continued service and contribution to the company.

Key Dates